LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined activities of LNK in solid tumors. In this study, we found by in silico analysis and staining tissue arrays that the levels of LNK expression were elevated in high-grade ovarian cancer. To test the functional importance of this observation, LNK was either overexpressed or silenced in several ovarian cancer cell lines. Remarkably, overexpression of LNK rendered the cells resistant to death induced by either serum starvation or nutrient deprivation, and generated larger tumors using a murine xenograft model. In contrast, silencing of LNK decreased ovarian cancer cell growth in vitro and in vivo. Western blot studies indicated that overexpression of LNK upregulated and extended the transduction of the mitogenic signal, whereas silencing of LNK produced the opposite effects. Furthermore, forced expression of LNK reduced cell size, inhibited cell migration and markedly enhanced cell adhesion. Liquid chromatography-mass spectroscopy identified 14-3-3 as one of the LNK-binding partners. Our results suggest that in contrast to the findings in hematologic malignancies, the adaptor protein LNK acts as a positive signal transduction modulator in ovarian cancers.
INTRODUCTION
The adaptor protein LNK (SH2B3) is a key negative regulator of the signaling pathway of hematopoietic receptors activated by growth factors, 1,2 thus having a critical role in hematopoiesis. 3 The protein contains a N-terminal proline-rich region that mediates dimerization, a pleckstrin homology domain and a Src homology 2 (SH2) domain that specifically binds to phosphorylated tyrosines and mediates signal transduction. 1 Previous studies showed that LNK knockout mice had splenomegaly and abnormal lymphoid and myeloid homeostasis. 4, 5 Subsequent studies revealed that LNK inhibited the activating signals mediated by thrombopoietin [6] [7] [8] and erythropoietin. 9 On the other hand, overexpression of LNK inhibited proliferation of hematopoietic transformed cells through the suppression of the kinase activity of oncogenic JAK2 V617F, 10, 11 MPL W515L, 12 c-KIT, 13, 14 c-FMS, 15 PDGFR/FIP1L1-PDGFRα and TEL-PDGFRβ, 16 as well as FLT3-ITD. 17 Recently, LNK mutations have also been found in patients with myeloproliferative neoplasms (MPN), [18] [19] [20] [21] early T-cell acute lymphoblastic leukemia, 22 Ph-like acute lymphoblastic leukemia, 23 B-precursor acute lymphoblastic leukemia 24 and Down syndrome-related myeloid disorders. 25 The mutational loss of function of LNK in hematopoietic cells releases its inhibitory activity against the activated tyrosine kinase receptors and its downstream Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, resulting in enhanced hematologic cell proliferation, thus fostering the development and progression of these hematopoietic neoplasms. 10 The resultant phenotype is reminiscent of the MPN-like features of LNK À /À mice. 26 Most of the studies that have explored the function of LNK focused on either normal or transformed hematologic cells;
recently, several studies have explored the effects of LNK on the function of normal endothelium cell. [27] [28] [29] To our knowledge, the role of LNK in solid tumors has not been addressed. Previously, while studying hematopoiesis, control experiments noted that forced overexpression of LNK did not inhibit the growth of several nonhematopoietic cell lines (NIH3T3 and 293T). 6 In an overview survey, we found that selected solid cancers expressed LNK, and forced overexpression of LNK in several solid cancer cell lines did not have a significant effect on their proliferation, suggesting that LNK may have a different role in solid tumor cells compared with hematologic dyscrasias. 30 This observation prompted us to do an in depth study of the effect of LNK in ovarian cancer cells. We chose this cancer because we previously noted that some ovarian cancer cell lines had detectable levels of LNK mRNA. 30 RESULT Elevated expression of LNK in ovarian cancers Previously, others 6 and our group 30 showed that overexpression of LNK inhibited cell growth and caused cell death in many leukemia cell lines, but similar experiments performed in several solid tumor cell lines had little effect on their proliferation, 30 suggesting that LNK might have a different role in solid tumor cells compared with those of the hematopoietic system. In silico analyses showed that rather than being downregulated as anticipated for a tumor suppressor, LNK is upregulated in several types of tumors including skin (melanoma), kidney and ovarian cancers ( Figure 1a ). Meanwhile, cancer copy number data from TCGA (The Cancer Genome Atlas) suggests that the LNK locus is amplified in several solid tumors including sarcoma (5.8%, 3/52 (18 h) and followed by addition of serum (2 h) . Confluent cultures were changed to serumfree medium for 18 h, and then switched back to complete medium containing 10% FBS for 2 h. Western blot was performed to examine the LNK protein at indicated time points. Ctrl (control cell grown in the complete medium containing 10% FBS). (g) Western blot of LNK in the ovarian cancer cell line OVCA433 with forced expressed LNK. Cells were SS (18 h) followed by serum stimulation (as described above) for 1-3 h, and LNK protein was examined by western blot. β-actin was used as loading control. cases in TCGA data set; or 2.4%, 5/207 cases in Memorial Sloan Kettering Cancer Center (MSKCC)/Broad data set), bladder cancer (3.8%, 1/26 cases) and ovarian cancer (2.3%, 7/311 cases) ( Supplementary Figure 1 ). Here we focused on ovarian cancer. LNK expression was examined in the microarray data of 1538 ovarian cancer patient samples, 142 ovarian cancer cell lines (molecular ovarian cancer subtypes were classified as described in Tan et al. 31 ) and benign ovarian cysts (Supplementary Figure 2) . Among the five different ovarian cancer subtypes (Epi-A, Epi-B, Mes, Stem-A and Stem-B), LNK mRNA expression is significantly elevated in the mesenchymal subtype in both patient samples and cell lines (Figure 1b ), Mesenchymal subtype includes more advanced stage and metastatic tumors; this subtype is associated with poorer outcomes. 31 This was further analyzed using cBio cancer genomics portal (http://www.cbioportal.org/public-portal/ index.do) of the TCGA data set. A total of 316 serous ovarian cancer samples were separated into LNK high-and low expression groups. Patients with a higher LNK expression showed a worse outcome compared with those with a lower LNK expression ( Figure 1c , left). In contrast, those patients having relative low LNK expression had a better survival (Figure 1c , right).
In addition, moderate LNK immunohistochemical (IHC) staining was observed in many serous cystadenocarcinoma and endometrioid carcinoma samples, especially in high-grade disease ( Overexpression of LNK renders the cells resistant to cell death Subsequently, we examined LNK protein expression in several ovarian cancer and melanoma cell lines by western blot. Unexpectedly, we found that the LNK protein levels were significantly upregulated during serum starvation (SS) then returned to baseline levels when the cells were restored to complete medium containing 10% fetal bovine serum (FBS). This was noted in the ovarian cancer cell lines such as A2008 and C13, as well as the melanoma cell lines M285 and M368 (Figure 1f and Supplementary Figure 5 ). We also observed this phenomenon in cells that stably contained a LNK expression vector whose level of LNK transcription was constantly driven by the CMV promoter ( Figure 1g ). Thus, accumulation of LNK protein with SS is probably a post-translational event.
To test the functional importance of this finding, we studied both forced expression and silencing of LNK in several ovarian cancer cell lines. Overexpression of LNK in the ovarian cancer cells OVCA433 significantly enhanced their cell survival during prolonged SS. After 9 days culture in serum-free RPMI medium, over 60% of the control green fluorescent protein (GFP) cells were dead. In contrast, almost all the LNK overexpressing cells survived, suggesting that LNK promoted cell survival in serum-free adverse conditions (Figures 2a (upper left panel) and b). In another set of complementary experiments, LNK protected ovarian cancer cells in even more adverse growth condition. LNK overexpressing cells displayed significantly higher survival rates than the GFP control cells after eliminating serum and growing in either 50 or 10% RPMI culture medium (replacing RPMI with PBS; Figure 2a , upper panel). Also, overexpression of LNK rendered the ovarian cancer cells resistant to death during exposure to either PI3 kinase inhibitor (LYS294002), multi-targeted receptor tyrosine kinase inhibitor (Sunitinib), inhibitor of transcription (Actinomycin D), chemotherapy drug (Pacitaxel), HSP90 inhibitor (17-DMAG) or mammalian Target of Rapamycin (mTOR) and AKT inhibitor (Supplementary Figure 6 ) further confirming the pro-survival effect produced by the gain of LNK expression ( Figure 2a ). This phenomenon was also observed to various degrees in the following three other ovarian cancer cell lines: CAOV2, OVCAR5 and C13 cultured in the absence of serum with the addition of only 10% RPMI and 90% PBS ( Figure 2c ), or cultured in the glucose deprivation media ( Supplementary Figure 7) . Western blot revealed that the p-AKT pro-survival signal pathway in the LNK expressing cells was strongly activated during starvation ( Figure 2d ). Phosphorylated P70S6 and JNK1/2 were also increased ( Figure 2d ). When both cell lines (GFP or LNK) were infected with lentivirus containing short hairpin RNA (shRNA) targeted to AKT1, the pro-survival effect of LNK was diminished in the presence of SS, suggesting that LNK activates the p-AKT pathway and protects the cells from cell death (Figure 2e ). LNK promotes tumor growth in an in vivo murine xenograft model Under optimal growth conditions, forced expression of LNK in 5/7 ovarian cancer cell lines had little effect on cell proliferation (Figure 3a) , whereas OV56 and OVCA433 had a slight inhibition of their cell growth. On the other hand, stable silencing of LNK using three different shRNAs slowed the proliferation of 6/8 ovarian cancer cell lines (Figure 3b ), including A2008, CAOV2, C13, OVCA433, OVCAR5 and OV56 (Figure 3b ). Cell cycle analysis was performed on OVCAR5, however, we did not find significant difference between the LNK and control cell (Supplementary Figure 8 ).
To observe the in vivo effect of LNK on cell growth, murine xenograft models were established by subcutaneous injection of either CAOV2, OVCAR5 or A2008 cells having either forced expression or silencing of LNK. Tumor sizes and weights were increased in all the cell lines with forced expression of LNK, especially the OVCAR5 tumors (Figure 3c , P-value 0.03). In contrast, silencing of LNK in these cell lines reduced their tumor sizes and weights. Taken together, LNK promotes tumor growth in three murine xenograft models. Western blot and IHC staining confirmed the LNK overexpression in these tumors (Figures 3d and e ).
LNK regulates mitogenic signaling
To investigate potential mechanisms by which LNK regulates cellular proliferation, major mitogenic signaling pathways were examined upon either gain or loss of LNK expression. In agreement with our notion that LNK might be a positive regulator in these cell lines, LNK expression enhanced several signaling pathways that are critical for cell proliferation and survival in two ovarian cancer cell lines such as OVCA433 and OVCAR5 ( Figure 4a ). Forced expression of LNK increased phosphorylation of AKT and JNK1/2 in both cell lines, as well as increasing phosphorylation levels of PDK1 and p70S6 in OVCA433, and phosphorylation level of p38 in OVCAR5. Of interest, similar to hematopoietic cells, LNK attenuated the modest basal levels of p-JAK2 in OVCA433 ( Figure 4a ). In contrast, stably silenced LNK using two shRNA in three ovarian cancer cell lines (A2008, CAOV2 and OVCAR5) resulted in downregulation of expression of p-PDK1, p-AKT, p-GSK3β and mitogen-activated protein kinase (MAPK) (p-p38 and p-JNK1/2) ( Figure 4b ). In further experiments, we examined in detail the alterations of mitogenic signaling upon serum stimulation in several ovarian cancer cell lines having either forced expression or silencing of LNK (Figures 4c-g). These cells were SS overnight followed by serum stimulation for different durations (20-120 min). The serum stimulated LNK overexpressing cells showed higher levels of p-AKT, p-P70S6 and p-ERK1/2 compared with similarly treated control cells, especially the OVCA433 and A2008 cells (Figure 4c ), whereas silencing of LNK generally generated the opposite effect (Figures 4e-g, right panels).
In agreement with our observations, a significant correlation can be noted between the endogenous levels of LNK and the activation status of MAPK pathway in the TCGA 316 ovarian cancer samples reverse-phase protein array (RPPA) data set. Ovarian cancer samples with high expression of LNK displayed high levels of p-AKT, p-mTOR, p-MAP2K1 and p-MAPK (p-ERK1/2, p-JNK1/2 and p-p38), whereas samples with lower LNK mRNA expression had lower phosphorylation levels of the above proteins (except p-AKT; Figures 4h-j).
LNK enhances cell attachment and inhibits cell migration
During cell passage, we noted that stable LNK overexpressing OVCA433 cells displayed a strong attachment to the tissue culture plate, requiring either a longer duration or higher concentration of trypsin to release them from the plates compared with control cells. In contrast, stable knockdown of LNK in these cell lines slightly reduced the length of exposure to trypsin in order to release them from the plates (data not shown). We, therefore, considered that LNK enhanced cell adhesion. To explore this hypothesis, OVCA433 cells were allowed to adhere to culture dishes in six-well plates until they reached confluence. Plates were washed with PBS (not containing calcium) and cultured in different percentages of PBS (95-100%) and RPMI (5-0%) for 3 h. This lead to disruption of calcium-dependent cell contact junction/adhesion and slowly release the cells. As anticipated, compared with GFP control cells, those with forced expression of LNK protein significantly retained their cell attachment to the plates as the culture media were replaced with increasing amounts of calcium-free PBS (Figure 5a ). In the presence of 99% PBS for 3 h, a total of 69% of the LNK expressing cell were still attached to the plates, compared with 18% of control cells.
Cell migration was measured using the wound healing assay (Figure 5b ). At 16 h after the wound scratch, LNK overexpressing OVCA433 cells maintained a nearly intact gap. In contrast, the GFP control cells nearly closed the healing gap, indicating that LNK indeed has a role in regulation of cell migration. In addition, transwell experiments found that LNK overexpressing ovarian cancer cells migrated significantly less than the GFP control cells (Figure 5c ).
LNK regulates cells size
Consistent with the notion that LNK may have a role in the cytoskeleton organization and regulate cellular shape, overexpression of LNK reduced the cell diameter of 5/6 ovarian cancer cell lines (Figure 5d ). In contrast, silencing of LNK generated the opposite effect (Figure 5e ). The cell diameter increased to various extents in the six ovarian cancer lines having one of three shRNA targeted to different regions of LNK. This was most prominent in A2008, C13, OVCA433 and SKOV3 ovarian cancer cell lines (Figure 5e ).
Pathway analysis of microarray data RNA microarray analysis was performed to examine the gene expression changes after forced expression of LNK in OVCA433. Compared with vector control cells, the experimental cells had a prominent upregulation/alteration of genes related to extracellular matrix (ECM) receptor interaction (P-value 7.91 E À 4 ), cell adhesion/attachment (P-value 1.46 E À 4 ), and molecules associated with cell-cell tight junctions (Figure 6a ). A heat map displays genes with altered expression related to cell adhesion, p53 signaling and the JAK-STAT pathway (Figure 6b ). Quantitative real-time PCR was performed to confirm some of the interesting genes. Several members of the cadherin family (CDH1, 3, 5 and 10) (contributes to cell attachment) and members of the claudin family (CLDN3, 6, 7 and 23) (critical for the cell-cell tight junction formation) were indeed upregulated in the LNK overexpressing cells (Figure 6c , top panel). Additional genes related to cell adhesion and cell-cell connection including AMOT, CGNL1, CGN, Laminin (LAMA3) and integrin (ITGA4) were also upregulated in the LNK overexpressing cells, as confirmed by real-time PCR (Figure 6c, upper panel) . In contrast, two matrix metallopeptidases associated with extracelluar matrix degradation and enhanced cell migration (MMP9 and MMP7) were downregulated in the LNK overexpressing cells (Figure 6c, upper panel) . Interestingly, several cyclins (CCNB1, CCND2 and CCNG2), as well as BCL2L1 (a potent inhibitor of cell death) were upregulated in cells with overexpression of LNK, which is consistent with their resistance to cell death. In addition, two phosphatases (DUSP5 and DUSP6) were Liquid chromatography-mass spectroscopy To investigate further the potential mechanism by which LNK regulates signal transduction, liquid chromatography-mass spectroscopy (LC-MS) was performed to identify possible LNK-binding proteins. LNK and the binding proteins were initially coimmunoprecipitated with V5 antibody from OVCA433 cells stably expressing V5-tagged LNK; the immunoprecipitated protein complex was extensively washed and analyzed by LC-MS. Proteins also present in the control (OVCA433 cells stably expressing GFP immunoprecipitated with either V5 antibody or normal IgG) were removed from the results, and the candidate binding partners are summarized (Figure 7a ). The protein 14-3-3, recently identified as a LNK-binding partner in hematologic cells, 32 appears at the top of the list (Figure 7a ). This binding was further confirmed by immunoprecipitation and western blot (Figure 7b ), suggesting that LNK also bound to this scaffold protein in ovarian cancer cells. Interestingly, several binding candidates (MLL3, ATRX, NCOR2 and NCOR7) are nuclear protein having important role in regulation of histone methylation, chromatin remodeling and control of transcription. Their presence on the list raises the possibility that LNK may also be active in the nucleus. SH2B1β, another member of the same family as LNK, shuttles between the plasma membrane, cytosol and nucleus; and its nuclear-cytosol cycling is critical to promote nerve growth factor (NGF)-mediated preneuronal cell differentiation. 33 Our protein fractionation and western blot experiments showed a small amount of LNK was indeed present in the nuclear protein fraction (Figure 7c ); the role of the nuclear LNK requires further study.
The following three phosphorylation modification of LNK were identified by MS (Figure 7d ): S-103, S-150 and S-330, and the phosphorylation modification were further confirmed by antibodies specifically targeting total phosphorylated serine/threonine (p-S/T; Figure 7b ). Among these sites, Serine-150 is the human LNK homolog of murine LNK S-129 (Figure 7e ), which after phosphorylation allows LNK to bind avidly to 14-3-3. 32 Phosphorylation (S-150) of human LNK is also predicted to mediate binding of the 14-3-3 (http://scansite.mit.edu/). This is consistent with our immunoprecipitation studies showing that 14-3-3 is bound to LNK (Figures 7a and b) . Also, both sites (S-150 and S-330) and their surrounding amino acids are highly conserved across many species (Figure 7e ), suggesting their biological importance. Our MS results covered the peptide fragments containing Y44, Y203, Y273, Y401, Y555 and Y572 of LNK, and no phosphorylation of tyrosine residues in these fragments was detected.
We further investigate the binding effect of the 14-3-3 to the LNK protein. OVCAR5 cells with forced expression of LNK were further infected with lentivirus containing either non-target shRNA or shRNA mixture targeted to three 14-3-3 members: tau, zeta and gamma. Reduction of the cell diameter ( Figure 7f ) and generating slightly larger tumors ( Figure 7g ) was observed in these cells, compared with tumors with forced expression of LNK alone (Figure 7g ). Taken together, these result suggested that release or loss of the 14-3-3 binding will further enhance the effect of LNK. 14-3-3 may suppress the activity of LNK by modulating the amount of 'freely available' LNK to participate in regulation of the signaling pathway. Base on these observations, a working model of LNK in ovarian cancer is proposed ( Supplementary Figure 9) .
DISCUSSION
LNK is a well-studied tumor suppressor gene in hematopoiesis. 6, 34, 35 It is mutated in hematopoietic malignancies including 3-5% of MPN samples, 10% of MPN evolved to acute myeloid leukemia and 5% of early T-cell leukemia (reviewed in Gery and Koeffler 34 ). These mutations appear to be a loss of function, that is, dampening an activated tyrosine kinase. Paradoxically, we show that LNK can exert tumor survival properties in ovarian cancer cells and promote tumor growth in in vivo models. Growth factor/cytokine signaling often governs the uptake of nutrients, which in turn determines concentrations of intracellular metabolites. Nutrient depletion as well as other stresses may trigger altered cellular pathway leading to either cell survival or apoptosis. 36 The AKT and MAPK pathways are among the major downstream signals activated by growth factors that are often deregulated in cancer. Increased expression of LNK in ovarian cancer cells upregulated and prolonged the activation of AKT and MAPK and rendered the cells resistant to death induced by either serum/nutrient starvation or drug treatments. In contrast, silencing of LNK in these cells decreased activated AKT and MAPK signaling and slowed their cell proliferation. A similar observation has been reported recently, showing that LNK protected normal endothelium cells from death and rendered them resistant to apoptosis induced by tumor necrosis factor and actinomycin-D, 29 suggesting that this pro-survival effect of LNK is not only limited to ovarian cancer cells. Our RNA array analysis suggested that metabolic pathways are enhanced in cells overexpressing LNK. We speculate that LNK enhancement of signal transduction pathways (for example, AKT and MAPK pathways) allows for sufficient nutrient uptake, even when cells are exposed to low nutrient/stress conditions, which in turn enables the cells to maintain their metabolic needs.
The mTOR has a central role in regulating cell growth (cell mass) and cell proliferation (cell numbers) in response to environmental cues such as nutrient availability and different types of stress. 37 LNK overexpression in ovarian cancer cells enhanced their proliferation and reduced their cell size, whereas silencing of LNK had the opposite affects. The phosphorylation levels of AKT (upstream of mTOR) and p70S6 (downstream of mTOR) were both increased upon LNK overexpression, suggesting that the mTOR pathway is upregulated by LNK in ovarian cancer cells.
The in vivo xenograft experiments showed that LNK can promote cell growth and generate bigger tumor. Why does LNK appear to function differently in leukemia cells versus ovarian cancer/normal endothelial cells? LNK does not have enzymatic activity; its function is totally dependent on its binding partners. LNK may behave similar to a 'buffer molecule' modulating direction, amplitude and duration of signal transduction of the binding partner. Notably, the other two members (SH2B1 and APS (SH2B2)) of this family of proteins, share similar sequence homologies, [38] [39] [40] and their stimulatory and inhibitory roles also appear to be cell-type and pathway dependent. Many hematopoietic malignancies including MPN act as classical 'activated kinase diseases' driven by a mutant-activated receptor tyrosine kinase (for example, FLT3-ITD and mutant c-KIT) or the downstream kinase, for example, JAK2 to propel proliferation and survival. Typically, these activated mutant tyrosine kinases phosphorylate LNK at a tyrosine residue that becomes the scaffold for other SH2 domain containing proteins to attenuate the activated tyrosine kinase. This represents a feedback mechanism. In contrast, most of the ovarian cancers contain mutations associated with alterations of pathway signaling by RB, PI3K/ RAS, Notch, BRCA1/2 and the FOXM1 transcription factor. 41 Thus, we hypothesize that most ovarian cancer cells do not depend on either mutant, activated JAK2 and/or mutant, activated type III receptor tyrosine kinase pathways. Instead, oncogenic drivers of ovarian cancer cells are downstream of these receptor tyrosine kinases. Thus, LNK may not have a significant inhibitory effect on transformed epithelial cells. Meanwhile, a recent study in Drosophila revealed that LNK regulates and enhances the insulin signaling by binding to the insulin receptor. 42, 43 Female flies who are homozygously mutant for LNK have much smaller ovaries containing few oocytes and are sterile due to an arrest in oogenesis. 42 These studies suggest that LNK is required for normal ovarian development in the Drosophila.
Our studies show that LNK affects cell adhesion, ECM interaction and possibly the integrin pathway of ovarian cancer cells. We observed that overexpression of LNK inhibited cell migration. Concordantly, bone marrow mast cell from LNK − / − mice were reported to display increased migration to a cytokine compared with the wild-type mast cells. 13 The authors attributed the phenotype of these bone marrow mast cell to upregulation of the RAC1, p-JNK1/2 and p-P38 pathway in the LNK − / − mice cells. 13 However, in ovarian cancer cells, our data suggest that the activated p-JNK1/2 and p-P38 pathway is associated with LNK expression and decreased migration. Consistent with our results, a recent study suggested that overexpression of LNK inhibits cell migration of normal endothelial cells; and the authors reached the conclusion that this phenomenon is associated with enhanced turnover of focal adhesion complexes and activation of the integrin pathway. 27 In addition, SH2B1 recently was also found to have a role in the regulation of focal adhesion complexes. 44 Of particular interest, our microarray analysis showed that a number of genes related to cell adhesion and ECM interaction (for example, E-cadherin and the cell-cell tight junction claudin family members) are upregulated in ovarian cancer cells that have high expression of LNK. At the same time, our MS results suggest that LNK might bind to the small G-protein RAB21 that is critical for integrin internalization, trafficking and redistribution. 45 Together, our data suggest that LNK may enhance cell attachment and attenuate cell migration by multiple mechanisms.
Besides participating in cell adhesion and ECM interaction, pathway analysis suggested a possible role of LNK in the JAK2-STAT signaling pathways; this is consistent with the function of LNK in hematopoietic cells. Interestingly, pathway analysis also suggests that LNK participates in the amino-acid metabolism pathway (Figure 6a ). In line with this observation, a prior study indicated that LNK was dysregulated when cells were placed in a cysteine-free environment. 46 Our MS results suggest that some nuclear proteins interact with LNK, which prompted us to examine the subcellular localization of LNK. Our protein fractionation studies found a small amount of LNK localized in the nucleus, implying that LNK may have some biological function in the nucleus. Notably, the well-known binding partner of LNK, JAK2, enters the nucleus and regulates transcription by phosphorylating the core histone H3. 47 Although we did not identify JAK2 binding to LNK by our MS, this is worthy of further exploration. Also of interest, several proteins related to the endocytic pathway (CLINT1, RAB21 and LYST) appear to bind to LNK as detected by MS. Generally in hematopoietic cells upon ligand stimulation, their receptor tyrosine kinases enter the endocytosis pathway, and in part undergo lysosomal degradation to prevent overactivation of these activated signaling pathways. LNK may aid in the attenuation of the tyrosine kinase activity through endocytic degradation.
In summary, our data identified for the first time several unique functions of LNK in ovarian cancer cells. LNK augmented the p-AKT and p-MAPK pathways, enhanced cell adhesion and slowed cell migration, and promoted the in vivo tumor growth in murine xenograft model. 14-3-3 was identified as one of the LNK-binding partner that can suppress LNK activity. Our results suggest that in contrast to the findings in hematologic malignancies, the adaptor protein LNK acts as a positive signal transduction modulator in ovarian cancers. We believe that our observations are novel and open a new area of inquiry for this important adaptor protein.
MATERIALS AND METHODS

Antibodies and reagents
The following antibodies were used in this study: anti-human LNK antibody (AF5888, R&D Systems (Minneapolis, MN, USA); a sheep IgG against Escherichia coli derived recombinant human LNK protein (amino acids 427-575)); murine anti-β-actin monoclonal antibody (Sigma-Aldrich, St Louis, MO, USA); V5 and pan 14-3-3 antibody (Abcam, Cambridge, MA, USA); antibodies against p-JAK2 (Tyr1007/1008), JAK2, p-p38 (Thr180/ Tyr182), p-ERK1/2 (Thr202/Tyr204), p-JNK1/2 (Tyr183), p-PDK1 (Ser243), p-P70S6 (Thr421/Ser424), p-GSK3beta (Ser9), p-AKT (Ser473) and AKT, p-PI3K p110δ (Tyr485) (obtained from either Cell Signaling Technology (Danvers, MA, USA) or Santa Cruz Biotechnology (Dallas, TX, USA)) and p-FAK Tyr861 (Epitomics, Burlingame, CA, USA).
Cell lines and cell culture
Ovarian cancer cell lines OVCA433, C13, A2008 and CAOV2 (provided by RY-J Huang, National University of Singapore (NUS)) and melanoma cell lines M285 and M368 (kindly provided by Antoni Ribas, University of California, Los Angeles (UCLA)) were maintained in RPMI 1640 containing 10% FBS with penicillin and streptomycin. The ovarian cancer cell line OVCAR5 was maintained in the same medium with 10 μg/ml insulin; OV7 and OV56 were maintained in DMEM Hi-Glucose/Ham's F-12 [1:1] plus 10% FBS, 0.5 μg/ml hydrocortisone and 10 μg/ml insulin. HEK293T cells were cultured in DMEM medium with 10% FBS. Cells were grown at 37°C with 5% CO 2 in humidified air.
Lentivirus and stable cell line generation
The pLKO.1-puro-CMV-TurboGFP lentivirus plasmid (SHC003) was obtained from Sigma-Aldrich. The entire coding region of huLNK, including the HIS tag and V5 tag, was amplified from pcDNA3 LNK using primers 5′-TGAGCTAGCATGAACGGGCCTGCCCTGCAGCC-3′ (Nhe I) and 5′-AAACA CGTGCTCGAGCGGCCGCCACTGT-3′ (Pml I). The PCR product was ligated to pGEM-T vector and validated by Sanger sequencing. This construct was digested with Nhe I and Pml I, the LNK-containing fragment was gel purified, and the GFP-coding fragment of pLKO-CMV-GFP vector (SHC003) was replaced with the LNK open reading frame (pLKO-CMV-LNK). For gene silencing, shRNA plasmids targeted to LNK (TRCN0000265715 (shRNA15), TRCN0000265716 (shRNA16), TRCN0000256095 (shRNA95) and Scramble shRNA SHC002) were purchased from Sigma. shRNA plasmids targeted to AKT1 (TRCN0000010174), 14-3-3 Q (YWHAQ, TRCN0000078169), 14-3-3 Z (YWHAZ, TRCN0000029404) and 14-3-3 G (YWHAG, TRCN0000078158) were generated according to the protocol described by Addgene (http:// www.addgene.org/tools/protocols/plko/). The sequences of all the shRNA constructs were confirmed by Sanger sequencing using the U6 primer.
Ovarian cancer tissue array analysis
Human ovarian cancer tissue array (OVC1021) was purchased from Biomax US (Rockville, MD, USA). Specifity of LNK antibody was validated by IHC staining of formalin-fixed and paraffin-embedded blocks either of silenced or overexpressed LNK OVCA433 cell. Detail process of IHC is described in the Supplementary Material.
Murine xenograft model
In vivo cell proliferative effects after either gain or lost of LNK was studied in a murine xenograft model. Five-to-six weeks old nonobese diabetic/ severe combined immunodeficiency (NOD/SCID) mice were used for the study. Two million (CAOV2 and A2008) or six million (OVCAR5) cells were resuspened in 100 μl FBS and 100 μl Matrix gel (BD Biosciences, San Jose, CA, USA), and subcutaneously injected into both flanks of immunodeficient Nod-SCID mice. The mice were killed, and the tumors were excised and weighted at the end of the experiments (days 18-28).
Microarray analysis
Microarray analyses were performed in triplicate using OVCA433 cells overexpressing LNK, compared with control cells containing GFP. The array hybridization was performed with Illumina (San Diego, CA, USA) Human HT-12 v4 Expression BeadChip, the pathway analysis was accomplished with KEGG and Biocarta database. Real-time RT-PCR was performed to validate the significantly changed genes.
Co-immunoprecipitation and LC-MS analysis
LNK overexpressing cell lines were placed into the protein lysis buffer (0.5% Nonidet P40, 50 mM Tris/HCl, pH 8.0, 150 mM NaCl with protease inhibitor cocktail and phosphatase inhibitors NaF and Na 3 VO 4 ) at 4°C for 15 min, and centrifuged at 12 000 r.p.m. (15 min, 4°C) to remove cell debris. Protein lysates were shaken overnight with V5 antibody at 4°C and collected by precipitation with protein A/G beads. After washing with protein lysis buffer three times, the protein binding to the protein A/G beads were eluted with 5 × SDS loading dye; the eluted samples were subsequently used for LC-MS analysis.
Method in supplemental material
Detailed methods for Lentivirus packaging, western blot, immunofluorescence microscopy and the assays for cell proliferation, cell adhesion and detachment, cell motility and invasion are provided in the Supplementary Material.
